CRVS
Companies
NASDAQ
Corvus Pharmaceuticals Inc.
Health Care
$3.93
-$1.42 (-26.54%)
Price Chart
Overview
About CRVS
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Market Cap
$127.0M
Volume
3.8M
Avg. Volume
2.9M
P/E Ratio
-5.8541665
Dividend Yield
0.00%
Employees
32.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.35
High Correlation
Volatility
High (0.88)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CRVS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$127.0M
Volume3.8M
P/E Ratio-5.85
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 26, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025